Brii Biosciences Future Growth
Future criteria checks 0/6
Brii Biosciences's earnings are forecast to decline at 7.4% per annum while its annual revenue is expected to grow at 14.5% per year. EPS is expected to grow by 27% per annum.
Key information
-7.4%
Earnings growth rate
27.0%
EPS growth rate
| Biotechs earnings growth | 42.6% |
| Revenue growth rate | 14.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 26 Aug 2024 |
Recent future growth updates
Recent updates
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans
Nov 19
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation
Jul 26Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth
Jan 12We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely
Sep 20We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn
Mar 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -490 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -505 | N/A | N/A | 1 |
| 12/31/2024 | -77 | -558 | N/A | N/A | 1 |
| 6/30/2024 | 38 | -265 | -516 | -466 | N/A |
| 3/31/2024 | 47 | -220 | -580 | -530 | N/A |
| 12/31/2023 | 56 | -175 | -644 | -594 | N/A |
| 9/30/2023 | 95 | -251 | -682 | -588 | N/A |
| 6/30/2023 | 134 | -327 | -720 | -581 | N/A |
| 3/31/2023 | 128 | -405 | -678 | -539 | N/A |
| 12/31/2022 | 122 | -484 | -636 | -496 | N/A |
| 9/30/2022 | 99 | -1,021 | -591 | -521 | N/A |
| 6/30/2022 | 75 | -1,558 | -546 | -546 | N/A |
| 3/31/2022 | 84 | -2,861 | -713 | -713 | N/A |
| 12/31/2021 | 93 | -4,164 | -880 | -879 | N/A |
| 9/30/2021 | 100 | -3,999 | -838 | -837 | N/A |
| 6/30/2021 | 107 | -3,835 | -796 | -794 | N/A |
| 3/31/2021 | 94 | -2,512 | -600 | -599 | N/A |
| 12/31/2020 | 82 | -1,190 | -404 | -404 | N/A |
| 12/31/2019 | 20 | -521 | -91 | -67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2137 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2137 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2137 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2137 is forecast to have no revenue next year.
High Growth Revenue: 2137 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2137's Return on Equity is forecast to be high in 3 years time